GC
GCTK
—
Nasdaq
Medical Equipment & Supplies
Glucotrack, Inc.
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
668,684 USD
P/E
—
EV / Rev
—
Div yield
—
Op margin
—
ROE
509,3 %
Net margin
—
Debt / equity
—
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
$0,31
Open
—
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About
Glucotrack, Inc. develops the Glucotrack CBGM, a non-invasive continuous blood glucose monitoring device, but has not yet commercialized the product or generated revenue.
Business. Glucotrack, Inc. (GCTK) is a medical device company operating within the Healthcare Equipment & Supplies sector. The firm is headquartered in the United States and is primarily listed on the Nasdaq stock exchange. As segment and geographic breakdowns are not specified, the company is described at the industry level as a provider of medical equipment and supplies.
Classification70 %
SectorHealthcare
Business sectorHealthcare Equipment & Supplies
Industry groupMedical Equipment, Supplies & Distribution
IndustryMedical Equipment & Supplies
ActivityMedical Devices
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership→
Geode Capital Management, L.L.C.
largest disclosed fund holder
Profitability→
509,3 %
return on equity
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to GCTK. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
Glucotrack, Inc. (GCTK) is a medical device company operating within the Healthcare Equipment & Supplies sector. The firm is headquartered in the United States and is primarily listed on the Nasdaq stock exchange. As segment and geographic breakdowns are not specified, the company is described at the industry level as a provider of medical equipment and supplies.
Classification70 %
SectorHealthcare
Business sectorHealthcare Equipment & Supplies
Industry groupMedical Equipment, Supplies & Distribution
IndustryMedical Equipment & Supplies
ActivityMedical Devices
AI synthesis
GENERATEDGlucotrack presents a distressed capital structure with negative total equity of $-851,000 and total liabilities of $5.2 million exceeding total assets of $4.4 million. The current ratio stands at 0.85, indicating current liabilities exceed current assets. While the company holds $3.9 million in cash and equivalents, operating cash flow was negative $4.0 million in Q1 2026. The negative debt-to-equity ratio reflects the negative equity base, and the market capitalization is approximately $477,000.
Profitability is deeply negative, with a net income loss of $4.3 million and operating income of $-4.2 million in Q1 2026. Return on assets is -0.99, and return on equity is reported as 5.09, a metric distorted by the negative equity denominator. The company has not yet commercialized its primary product, resulting in zero revenue and no positive earnings to compare against cohort medians.
Key takeaways
- Glucotrack has negative equity of $-851,000 and a current ratio of 0.85, signaling severe liquidity constraints.
- The company has not yet commercialized its Glucotrack CBGM, resulting in zero revenue and ongoing operating losses.
- Share count expanded from 13,193 to 2.5 million between 2024 and 2026, indicating significant dilution from equity issuances.
- Filings explicitly state going-concern doubts, highlighting the risk that the company may not secure sufficient financing to continue operations.
- Recent stock price volatility includes a 20.7% single-day drop in July 2026, reflecting market skepticism about the company's near-term prospects.
Bull / Bear case
Generated · model-assisted— missing data
In focus — financials by report
Quarterly
Annual
QUARTERLYFiled 2026-03-31
Q4 2025 · Quarter highlights
Operating income -$4.2M.
Revenue—
Operating income-$4.2M
Net income-$4.3M
Free cash flow—
EPS—
Operating cash flow-$4.0M
Financials
Income statement
Revenue—
Gross profit—
Operating income-$4.2M
Net income-$4.3M
Balance sheet
Total assets$4.4M
Total liabilities$5.2M
Total equity-$851.0k
Cash & equivalents$3.9M
Long-term debt—
Cash flow
Operating cash flow-$4.0M
CapEx—
Free cash flow—
SBC$61.0k
Highlights
- ▍Operating income -$4.2M
QUARTERLYFiled 2025-09-30
Q2 2025 · Quarter highlights
Operating income -$12.6M.
Revenue—
Operating income-$12.6M
Net income-$15.8M
Free cash flow-$11.4M
EPS—
Operating cash flow-$11.3M
Financials
Income statement
Revenue—
Gross profit—
Operating income-$12.6M
Net income-$15.8M
Balance sheet
Total assets$8.3M
Total liabilities$5.5M
Total equity$2.8M
Cash & equivalents$7.9M
Long-term debt—
Cash flow
Operating cash flow-$11.3M
CapEx$76.0k
Free cash flow-$11.4M
SBC$121.0k
Highlights
- ▍Operating income -$12.6M
QUARTERLYFiled 2025-06-30
Q1 2025 · Quarter highlights
Operating income -$8.3M.
Revenue—
Operating income-$8.3M
Net income-$11.6M
Free cash flow-$6.7M
EPS—
Operating cash flow-$6.7M
Financials
Income statement
Revenue—
Gross profit—
Operating income-$8.3M
Net income-$11.6M
Balance sheet
Total assets$10.2M
Total liabilities$3.3M
Total equity$6.9M
Cash & equivalents$9.6M
Long-term debt—
Cash flow
Operating cash flow-$6.7M
CapEx$9.0k
Free cash flow-$6.7M
SBC$80.0k
Highlights
- ▍Operating income -$8.3M
ANNUALFiled 2025-12-31
FY 2025 · Full-year highlights
Operating income -$16.1M.
Revenue—
Operating income-$16.1M
Net income-$19.4M
Free cash flow-$15.3M
EPS—
Operating cash flow-$15.2M
Financials
Income statement
Revenue—
Gross profit—
Operating income-$16.1M
Net income-$19.4M
Balance sheet
Total assets$7.8M
Total liabilities$5.0M
Total equity$2.8M
Cash & equivalents$7.4M
Long-term debt—
Cash flow
Operating cash flow-$15.2M
CapEx$96.0k
Free cash flow-$15.3M
SBC$211.0k
Highlights
- ▍Operating income -$16.1M
ANNUALFiled 2024-12-31
FY 2024 · Full-year highlights
Operating income -$14.5M.
Revenue—
Operating income-$14.5M
Net income-$22.6M
Free cash flow-$12.6M
EPS—
Operating cash flow-$12.5M
Financials
Income statement
Revenue—
Gross profit—
Operating income-$14.5M
Net income-$22.6M
Balance sheet
Total assets$5.9M
Total liabilities$18.9M
Total equity-$13.0M
Cash & equivalents$5.6M
Long-term debt—
Cash flow
Operating cash flow-$12.5M
CapEx$104.0k
Free cash flow-$12.6M
SBC$173.0k
Highlights
- ▍Operating income -$14.5M
ANNUALFiled 2024-12-31
FY 2025 · Full-year highlights
Operating income -$14.5M.
Revenue—
Operating income-$14.5M
Net income-$22.6M
Free cash flow-$12.6M
EPS—
Operating cash flow-$12.5M
Financials
Income statement
Revenue—
Gross profit—
Operating income-$14.5M
Net income-$22.6M
Balance sheet
Total assets$5.9M
Total liabilities$18.9M
Total equity-$13.0M
Cash & equivalents$5.6M
Long-term debt—
Cash flow
Operating cash flow-$12.5M
CapEx$104.0k
Free cash flow-$12.6M
SBC$173.0k
Highlights
- ▍Operating income -$14.5M
ANNUALFiled 2023-12-31
FY 2023 · Full-year highlights
Operating income -$7.1M.
Revenue—
Operating income-$7.1M
Net income-$7.1M
Free cash flow—
EPS—
Operating cash flow-$6.6M
Financials
Income statement
Revenue—
Gross profit—
Operating income-$7.1M
Net income-$7.1M
Balance sheet
Total assets$4.9M
Total liabilities$1.7M
Total equity$3.2M
Cash & equivalents$4.5M
Long-term debt—
Cash flow
Operating cash flow-$6.6M
CapEx—
Free cash flow—
SBC$281.0k
Highlights
- ▍Operating income -$7.1M
ANNUALFiled 2023-12-31
FY 2024 · Full-year highlights
Operating income -$7.1M.
Revenue—
Operating income-$7.1M
Net income-$7.1M
Free cash flow—
EPS—
Operating cash flow-$6.6M
Financials
Income statement
Revenue—
Gross profit—
Operating income-$7.1M
Net income-$7.1M
Balance sheet
Total assets$4.9M
Total liabilities$1.7M
Total equity$3.2M
Cash & equivalents$4.5M
Long-term debt—
Cash flow
Operating cash flow-$6.6M
CapEx—
Free cash flow—
SBC$281.0k
Highlights
- ▍Operating income -$7.1M
Valuation FY
Market price
$0,41
Market cap
$477.0k
Enterprise valueⓘ
-$3.5M
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
—
P / Tangible bookⓘ
—
Tangible book
-$851.0k
Net cashⓘ
$3.9M
Current ratioⓘ
0.8
Debt / equityⓘ
—
ROAⓘ
-99.5%
ROEⓘ
5.1%
Cash conversionⓘ
93.0%
CapEx / revenueⓘ
—
SBC / revenueⓘ
—
Dilution ratioⓘ
-35.1%
Revenue by segment
Business relationships
— missing data
Supply chain
— missing data
Peer comparison
— missing data
Market position
Stress test
— missing data
Predictor forecast
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
— missing data
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskMedium
Liquidity riskHigh
Filing-based flags
- Current liabilities exceed current assets.
- Filings reference going-concern or substantial-doubt language.
- Source documents mention dilution or offering risk.
Benchmarks vs cohort
ROE509,3 %Best in class
D/E-0,00Above median
Cash Conv0,93Above median
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net acquired 12 165 sh3 grants3 insiders
- Director · Stock option (right to buy) → Common Stock, par value $0.001 per shareAcquired 4 055 @ $7,40grant · 2025-10-03
- Director · Stock option (right to buy) → Common Stock, par value $0.001 per shareAcquired 4 055 @ $7,40grant · 2025-10-03
- Director · Stock option (right to buy) → Common Stock, par value $0.001 per shareAcquired 4 055 @ $7,40grant · 2025-10-03
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Regulatory filings
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Reference data
How metrics are computed
- Return On Equitynet_income / total_equity
- Enterprise Valuemarket_cap - net_cash
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Market Capmarket_price * shares_outstanding_diluted
Source documents
- Glucotrack, Inc. company facts · 2026-07-26
- Glucotrack, Inc. 10-Q 2026-05-14 · 2026-07-26
- Glucotrack, Inc. 10-K 2026-03-30 · 2026-07-26
- Glucotrack, Inc. 10-Q 2025-11-13 · 2026-07-26
- Glucotrack, Inc. 10-Q 2025-08-14 · 2026-07-26
- ha_price_move fired on GCTK · 2026-07-26
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
Insider activity
Mixed / flat0 buys · 0 sellsnet $03 insiders · last 365d
- Director · Common Stock, par value $0.001 per shareOther 1 285 · 2025-10-03
- Director · Common Stock, par value $0.001 per shareOther 463 · 2025-10-03
- Director · Common Stock, par value $0.001 per shareOther 386 · 2025-10-03
Short positioning
2.4Mshares short+368.1% vs prior
1days to cover
44.2%short of daily vol
40.9Kfails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
GCTKCanonical
Nasdaq · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskMedium
Liquidity riskHigh
Current liabilities exceed current assets.
Filings reference going-concern or substantial-doubt language.
Source documents mention dilution or offering risk.
Evidence & claims
From filings & derived data- Cash & equivalents (annual): USD 7.38MUnknown
- Operating income (annual): USD -16.09MUnknown
- R&D expense (annual): USD 9.81MUnknown
- Capex (annual): USD 96KUnknown
- Total liabilities (annual): USD 5.01MUnknown
- Net income (annual): USD -19.39MUnknown
- Shares outstanding (annual): 910.69KUnknown
- Shareholders' equity (annual): USD 2.83MUnknown
- Operating cash flow (annual): USD -15.24MUnknown
- Total assets (annual): USD 7.84MUnknown
- Current liabilities (annual): USD 4.77MUnknown
- EPS (basic) (annual): USD-PER-SHARES 31Unknown
- Current assets (annual): USD 7.67MUnknown
- EPS (diluted) (annual): USD-PER-SHARES 31Unknown
- Total operating expenses (annual): USD 16.09MUnknown
- Total assets (annual): USD 5.93MUnknown
- Current assets (annual): USD 5.77MUnknown
- Operating income (annual): USD -14.55MUnknown
- Total operating expenses (annual): USD 14.55MUnknown
- Operating cash flow (annual): USD -12.49MUnknown
- Cash & equivalents (annual): USD 5.62MUnknown
- Shares outstanding (annual): 13.41KUnknown
- Total liabilities (annual): USD 18.93MUnknown
- Shareholders' equity (annual): USD -13MUnknown
Showing 24 of 31 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
2026-07-29 22:34 UTCEVENTHa Price Listing GCTK remains DEFICIENT (NASDAQ) — cure period. closed below $1.00 for 77 consecutive trading days (last close $0.46). cure deadline 2027-01-17 (172 days remaining).
2026-07-23 21:52 UTCEVENTHa Price Move GCTK extraordinary down move (-20.676% 1d, 0.85x sigma) on x2.798 volume
2026-03-31EARNINGSQuarterly results — Q4 2025 Net USD -4.3M
2025-12-31EARNINGSQuarterly results — Q3 2025
2025-12-31EARNINGSAnnual results — FY 2025 Net USD -19.4M
2025-10-03 00:00 UTCINSIDER6 insider transactions — 2025-10 3 derivative
2025-10-03INSIDERMalave Luis transacted 463 sh Common Stock, par value $0.001 per share — Director
2025-10-03INSIDERBalo Andrew K transacted 1.3k sh Common Stock, par value $0.001 per share — Director
2025-10-03INSIDERCarter Erin Catherine transacted 386 sh Common Stock, par value $0.001 per share — Director
2025-10-03INSIDERMalave Luis acquired 4.1k sh Stock option (right to buy) — Director
2025-10-03INSIDERBalo Andrew K acquired 4.1k sh Stock option (right to buy) — Director
2025-10-03INSIDERCarter Erin Catherine acquired 4.1k sh Stock option (right to buy) — Director
2025-09-30EARNINGSQuarterly results — Q2 2025 Net USD -15.8M
2025-07-11 00:00 UTCINSIDER3 insider transactions — 2025-07
2025-06-30EARNINGSQuarterly results — Q1 2025 Net USD -11.6M
2025-03-26 00:00 UTCINSIDER20 insider transactions — 2025-03 5 derivative
2025-02-05 00:00 UTCINSIDER1 insider transaction — 2025-02
2024-12-31EARNINGSAnnual results — FY 2024 Net USD -22.6M
2024-11-14 00:00 UTCINSIDER18 insider transactions — 2024-11 · net buy $8.5M 13 derivative
2024-07-30 00:00 UTCINSIDER12 insider transactions — 2024-07 12 derivative
2024-06-14 00:00 UTCINSIDER1 insider transaction — 2024-06 1 derivative
2024-04-22 00:00 UTCINSIDER5 insider transactions — 2024-04 · net buy $230k
2023-12-31EARNINGSAnnual results — FY 2023 Net USD -7.1M
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data
Premium coverage